company background image
1BT logo

Enlivex Therapeutics DB:1BT Stock Report

Last Price

€3.70

Market Cap

€71.5m

7D

2.2%

1Y

15.2%

Updated

18 Mar, 2024

Data

Company Financials +

1BT Stock Overview

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.

1BT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Enlivex Therapeutics Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enlivex Therapeutics
Historical stock prices
Current Share PriceUS$3.70
52 Week HighUS$3.84
52 Week LowUS$1.20
Beta1.0
1 Month Change26.71%
3 Month Change189.06%
1 Year Change15.19%
3 Year Change-67.26%
5 Year Changen/a
Change since IPO-62.96%

Recent News & Updates

Recent updates

Shareholder Returns

1BTDE BiotechsDE Market
7D2.2%-3.8%0.8%
1Y15.2%23.4%6.2%

Return vs Industry: 1BT underperformed the German Biotechs industry which returned 23.4% over the past year.

Return vs Market: 1BT exceeded the German Market which returned 6.2% over the past year.

Price Volatility

Is 1BT's price volatile compared to industry and market?
1BT volatility
1BT Average Weekly Movement21.2%
Biotechs Industry Average Movement5.8%
Market Average Movement4.7%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 1BT's share price has been volatile over the past 3 months.

Volatility Over Time: 1BT's weekly volatility has increased from 14% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aOren Hershkovitzhttps://www.enlivex.com

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.

Enlivex Therapeutics Ltd. Fundamentals Summary

How do Enlivex Therapeutics's earnings and revenue compare to its market cap?
1BT fundamental statistics
Market cap€71.53m
Earnings (TTM)-€24.99m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1BT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$27.16m
Earnings-US$27.16m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.46
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 1BT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.